Skip to main content
Top
Published in: AIDS and Behavior 1/2015

01-01-2015 | Original Paper

Four Types of Barriers to Adherence of Antiretroviral Therapy are Associated with Decreased Adherence Over Time

Authors: Becky L. Genberg, Yoojin Lee, William H. Rogers, Ira B. Wilson

Published in: AIDS and Behavior | Issue 1/2015

Login to get access

Abstract

The objectives of this study were to understand how different types of barriers to adherence to antiretroviral therapy (ART) were related and their differential impact on objectively measured adherence over time. Data from 151 patients taking ART were used to describe four sub-types of self-reported adherence barriers: medication and health concerns (MHC), stigma (S), family responsibilities (FR), and problems with schedule and routine (PSR). Generalized linear models with generalized estimating equations (GEE) were used to examine the impact of barriers on adherence over time. The sample was 23 % female, mean age 42 years, with 26 % African-American and 20 % Hispanic. The overall average adherence was 73 %. Patients reported at least one PSR barrier in 66 % of study visits, MHC in 40 %, S in 17 %, and FR in 6 %. In 40 % of visits, patients reported two or more barrier sub-types. There were statistically significant (p ≤ 0.05) decreases of 3.9, 2.5, and 2.4 in percent adherence, for MHC, PSR, and S, respectively, per unit increase in barrier score. Interventions to address different types of patient-identified barriers to ART adherence using targeted approaches are needed.
Literature
1.
go back to reference Bangsberg DR, Perry S, Charlebois ED, et al. Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS. 2001;15(9):1181–3.PubMedCrossRef Bangsberg DR, Perry S, Charlebois ED, et al. Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS. 2001;15(9):1181–3.PubMedCrossRef
2.
go back to reference Mills EJ, Nachega JB, Bangsberg DR, et al. Adherence to HAART: a systematic review of developed and developing nation patient-reported barriers and facilitators. PLoS Med. 2006;3(11):e438.PubMedCentralPubMedCrossRef Mills EJ, Nachega JB, Bangsberg DR, et al. Adherence to HAART: a systematic review of developed and developing nation patient-reported barriers and facilitators. PLoS Med. 2006;3(11):e438.PubMedCentralPubMedCrossRef
3.
go back to reference Ammassari A, Trotta MP, Murri R, et al. Correlates and predictors of adherence to highly active antiretroviral therapy: overview of published literature. J Acquir Immune Defic Syndr. 2002;31(Suppl 3):S123–7.PubMedCrossRef Ammassari A, Trotta MP, Murri R, et al. Correlates and predictors of adherence to highly active antiretroviral therapy: overview of published literature. J Acquir Immune Defic Syndr. 2002;31(Suppl 3):S123–7.PubMedCrossRef
5.
go back to reference Fogarty L, Roter D, Larson S, Burke J, Gillespie J, Levy R. Patient adherence to HIV medication regimens: a review of published and abstract reports. Patient Educ Couns. 2002;46(2):93–108.PubMedCrossRef Fogarty L, Roter D, Larson S, Burke J, Gillespie J, Levy R. Patient adherence to HIV medication regimens: a review of published and abstract reports. Patient Educ Couns. 2002;46(2):93–108.PubMedCrossRef
6.
go back to reference Konkle-Parker DJ, Erlen JA, Dubbert PM. Barriers and facilitators to medication adherence in a southern minority population with HIV disease. J Assoc Nurses AIDS Care. 2008;19(2):98–104.PubMedCentralPubMedCrossRef Konkle-Parker DJ, Erlen JA, Dubbert PM. Barriers and facilitators to medication adherence in a southern minority population with HIV disease. J Assoc Nurses AIDS Care. 2008;19(2):98–104.PubMedCentralPubMedCrossRef
7.
go back to reference Konkle-Parker D. Medication adherence: what are the barriers and facilitators? HIV Clin. 2007;19(4):8–9.PubMed Konkle-Parker D. Medication adherence: what are the barriers and facilitators? HIV Clin. 2007;19(4):8–9.PubMed
8.
go back to reference Roberts KJ. Barriers to and facilitators of HIV-positive patients’ adherence to antiretroviral treatment regimens. AIDS Patient Care STDS. 2000;14(3):155–68.PubMedCrossRef Roberts KJ. Barriers to and facilitators of HIV-positive patients’ adherence to antiretroviral treatment regimens. AIDS Patient Care STDS. 2000;14(3):155–68.PubMedCrossRef
9.
go back to reference Roberts KJ, Mann T. Barriers to antiretroviral medication adherence in HIV-infected women. AIDS Care. 2000;12(4):377–86.PubMedCrossRef Roberts KJ, Mann T. Barriers to antiretroviral medication adherence in HIV-infected women. AIDS Care. 2000;12(4):377–86.PubMedCrossRef
10.
go back to reference Proctor VE, Tesfa A, Tompkins DC. Barriers to adherence to highly active antiretroviral therapy as expressed by people living with HIV/AIDS. AIDS Patient Care STDS. 1999;13(9):535–44.PubMedCrossRef Proctor VE, Tesfa A, Tompkins DC. Barriers to adherence to highly active antiretroviral therapy as expressed by people living with HIV/AIDS. AIDS Patient Care STDS. 1999;13(9):535–44.PubMedCrossRef
11.
go back to reference Murphy DA, Roberts KJ, Martin DJ, Marelich W, Hoffman D. Barriers to antiretroviral adherence among HIV-infected adults. AIDS Patient Care STDS. 2000;14(1):47–58.PubMedCrossRef Murphy DA, Roberts KJ, Martin DJ, Marelich W, Hoffman D. Barriers to antiretroviral adherence among HIV-infected adults. AIDS Patient Care STDS. 2000;14(1):47–58.PubMedCrossRef
12.
go back to reference Remien RH, Hirky AE, Johnson MO, Weinhardt LS, Whittier D, Le GM. Adherence to medication treatment: a qualitative study of facilitators and barriers among a diverse sample of HIV+ men and women in four US cities. AIDS Behav. 2003;7(1):61–72.PubMedCrossRef Remien RH, Hirky AE, Johnson MO, Weinhardt LS, Whittier D, Le GM. Adherence to medication treatment: a qualitative study of facilitators and barriers among a diverse sample of HIV+ men and women in four US cities. AIDS Behav. 2003;7(1):61–72.PubMedCrossRef
13.
go back to reference Vervoort SC, Borleffs JC, Hoepelman AI, Grypdonck MH. Adherence in antiretroviral therapy: a review of qualitative studies. AIDS. 2007;21(3):271–81.PubMedCrossRef Vervoort SC, Borleffs JC, Hoepelman AI, Grypdonck MH. Adherence in antiretroviral therapy: a review of qualitative studies. AIDS. 2007;21(3):271–81.PubMedCrossRef
14.
go back to reference Rao D, Kekwaletswe TC, Hosek S, Martinez J, Rodriguez F. Stigma and social barriers to medication adherence with urban youth living with HIV. AIDS Care. 2007;19(1):28–33.PubMedCrossRef Rao D, Kekwaletswe TC, Hosek S, Martinez J, Rodriguez F. Stigma and social barriers to medication adherence with urban youth living with HIV. AIDS Care. 2007;19(1):28–33.PubMedCrossRef
15.
go back to reference Wilson IB, Laws MB, Safren SA, et al. Provider-focused intervention increases adherence-related dialogue but does not improve antiretroviral therapy adherence in persons with HIV. J Acquir Immune Defic Syndr. 2010;53(3):338–47.PubMedCentralPubMedCrossRef Wilson IB, Laws MB, Safren SA, et al. Provider-focused intervention increases adherence-related dialogue but does not improve antiretroviral therapy adherence in persons with HIV. J Acquir Immune Defic Syndr. 2010;53(3):338–47.PubMedCentralPubMedCrossRef
16.
go back to reference Rogers WH, Wilson IB, Bungay KM, Cynn DJ, Adler DA. Assessing the performance of a new depression screener for primary care (PC-SAD). J Clin Epidemiol. 2002;55(2):164–75.PubMedCrossRef Rogers WH, Wilson IB, Bungay KM, Cynn DJ, Adler DA. Assessing the performance of a new depression screener for primary care (PC-SAD). J Clin Epidemiol. 2002;55(2):164–75.PubMedCrossRef
17.
go back to reference Genberg BL, Wilson IB, Bangsberg DR, et al. Patterns of antiretroviral therapy adherence and impact on HIV RNA among patients in North America. AIDS. 2012;26(11):1415–23.PubMedCentralPubMedCrossRef Genberg BL, Wilson IB, Bangsberg DR, et al. Patterns of antiretroviral therapy adherence and impact on HIV RNA among patients in North America. AIDS. 2012;26(11):1415–23.PubMedCentralPubMedCrossRef
18.
go back to reference Bangsberg DR, Kroetz DL, Deeks SG. Adherence-resistance relationships to combination HIV antiretroviral therapy. Curr HIV/AIDS Rep. 2007;4(2):65–72.PubMedCrossRef Bangsberg DR, Kroetz DL, Deeks SG. Adherence-resistance relationships to combination HIV antiretroviral therapy. Curr HIV/AIDS Rep. 2007;4(2):65–72.PubMedCrossRef
19.
go back to reference Norton WE, Amico KR, Fisher WA, et al. Information-motivation-behavioral skills barriers associated with intentional versus unintentional ARV non-adherence behavior among HIV + patients in clinical care. AIDS Care. 2010;22(8):979–87.PubMedCentralPubMedCrossRef Norton WE, Amico KR, Fisher WA, et al. Information-motivation-behavioral skills barriers associated with intentional versus unintentional ARV non-adherence behavior among HIV + patients in clinical care. AIDS Care. 2010;22(8):979–87.PubMedCentralPubMedCrossRef
20.
go back to reference Vervoort SC, Grypdonck MH, de Grauwe A, Hoepelman AI, Borleffs JC. Adherence to HAART: processes explaining adherence behavior in acceptors and non-acceptors. AIDS Care. 2009;21(4):431–8.PubMedCrossRef Vervoort SC, Grypdonck MH, de Grauwe A, Hoepelman AI, Borleffs JC. Adherence to HAART: processes explaining adherence behavior in acceptors and non-acceptors. AIDS Care. 2009;21(4):431–8.PubMedCrossRef
21.
go back to reference MacDonell K, Naar-King S, Huszti H, Belzer M. Barriers to medication adherence in behaviorally and perinatally infected youth living with HIV. AIDS Behav. 2013;17(1):86–93.PubMedCentralPubMedCrossRef MacDonell K, Naar-King S, Huszti H, Belzer M. Barriers to medication adherence in behaviorally and perinatally infected youth living with HIV. AIDS Behav. 2013;17(1):86–93.PubMedCentralPubMedCrossRef
22.
go back to reference Murphy DA, Sarr M, Durako SJ, et al. Barriers to HAART adherence among human immunodeficiency virus-infected adolescents. Arch Pediatr Adolesc Med. 2003;157(3):249–55.PubMedCrossRef Murphy DA, Sarr M, Durako SJ, et al. Barriers to HAART adherence among human immunodeficiency virus-infected adolescents. Arch Pediatr Adolesc Med. 2003;157(3):249–55.PubMedCrossRef
23.
go back to reference Simoni JM, Amico KR, Pearson CR, Malow R. Strategies for promoting adherence to antiretroviral therapy: a review of the literature. Curr Infect Dis Rep. 2008;10(6):515–21.PubMedCentralPubMedCrossRef Simoni JM, Amico KR, Pearson CR, Malow R. Strategies for promoting adherence to antiretroviral therapy: a review of the literature. Curr Infect Dis Rep. 2008;10(6):515–21.PubMedCentralPubMedCrossRef
24.
go back to reference Mbuagbaw L, van der Kop ML, Lester RT et al. Mobile phone text messages for improving adherence to antiretroviral therapy (ART): an individual patient data meta-analysis of randomised trials. BMJ Open 2013;3(12):e003950. Mbuagbaw L, van der Kop ML, Lester RT et al. Mobile phone text messages for improving adherence to antiretroviral therapy (ART): an individual patient data meta-analysis of randomised trials. BMJ Open 2013;3(12):e003950.
25.
go back to reference Feldman BJ, Fredericksen RJ, Crane PK, et al. Evaluation of the single-item self-rating adherence scale for use in routine clinical care of people living with HIV. AIDS Behav. 2013;17(1):307–18.PubMedCentralPubMedCrossRef Feldman BJ, Fredericksen RJ, Crane PK, et al. Evaluation of the single-item self-rating adherence scale for use in routine clinical care of people living with HIV. AIDS Behav. 2013;17(1):307–18.PubMedCentralPubMedCrossRef
26.
go back to reference Schackman BR, Dastur Z, Rubin DS, et al. Feasibility of using audio computer-assisted self-interview (ACASI) screening in routine HIV care. AIDS Care. 2009;21(8):992–9.PubMedCrossRef Schackman BR, Dastur Z, Rubin DS, et al. Feasibility of using audio computer-assisted self-interview (ACASI) screening in routine HIV care. AIDS Care. 2009;21(8):992–9.PubMedCrossRef
27.
go back to reference Gonzalez JS, Batchelder AW, Psaros C, Safren SA. Depression and HIV/AIDS treatment nonadherence: a review and meta-analysis. J Acquir Immune Defic Syndr. 2011;58(2):181–7.PubMed Gonzalez JS, Batchelder AW, Psaros C, Safren SA. Depression and HIV/AIDS treatment nonadherence: a review and meta-analysis. J Acquir Immune Defic Syndr. 2011;58(2):181–7.PubMed
28.
go back to reference Starace F, Ammassari A, Trotta MP, et al. Depression is a risk factor for suboptimal adherence to highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2002;31(Suppl 3):S136–9.PubMedCrossRef Starace F, Ammassari A, Trotta MP, et al. Depression is a risk factor for suboptimal adherence to highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2002;31(Suppl 3):S136–9.PubMedCrossRef
29.
go back to reference Wendel CS, Mohler MJ, Kroesen K, Ampel NM, Gifford AL, Coons SJ. Barriers to use of electronic adherence monitoring in an HIV clinic. Ann Pharmacother. 2001;35(9):1010–5.PubMedCrossRef Wendel CS, Mohler MJ, Kroesen K, Ampel NM, Gifford AL, Coons SJ. Barriers to use of electronic adherence monitoring in an HIV clinic. Ann Pharmacother. 2001;35(9):1010–5.PubMedCrossRef
Metadata
Title
Four Types of Barriers to Adherence of Antiretroviral Therapy are Associated with Decreased Adherence Over Time
Authors
Becky L. Genberg
Yoojin Lee
William H. Rogers
Ira B. Wilson
Publication date
01-01-2015
Publisher
Springer US
Published in
AIDS and Behavior / Issue 1/2015
Print ISSN: 1090-7165
Electronic ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-014-0775-2

Other articles of this Issue 1/2015

AIDS and Behavior 1/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.